Validated using a knockout cell line
Recombinant
RabMAb

Anti-PTEN antibody [EPR9941-2] (ab170941)

Overview

  • Product name
    Anti-PTEN antibody [EPR9941-2]
    See all PTEN primary antibodies
  • Description
    Rabbit monoclonal [EPR9941-2] to PTEN
  • Tested applications
    Suitable for: IHC-P, WB, ICC/IF, Flow Cytmore details
    Unsuitable for: IP
  • Species reactivity
    Reacts with: Mouse, Rat, Human
  • Immunogen

    Recombinant fragment within Human PTEN aa 1 to the C-terminus. The exact sequence is proprietary.
    Database link: P60484

  • Positive control
    • WB: HeLa, MCF7 and 293T cell lysates. IHC-P: Human breast carcinoma and colon tissues. ICC/IF: HeLa cells.
  • General notes

    This product is a recombinant rabbit monoclonal antibody.

    Alternative versions available:

    Anti-PTEN antibody (Alexa Fluor® 488) [EPR9941-2] (ab202661)

    Anti-PTEN antibody (HRP) [EPR9941-2] (ab202358)

    Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMab® patents

Properties

Applications

Our Abpromise guarantee covers the use of ab170941 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
IHC-P 1/50 - 1/100. Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.
WB 1/1000 - 1/5000. Predicted molecular weight: 47 kDa.
ICC/IF 1/500.
Flow Cyt Use at an assay dependent concentration.
  • Application notes
    Is unsuitable for IP.
  • Target

    • Function
      Tumor suppressor. Acts as a dual-specificity protein phosphatase, dephosphorylating tyrosine-, serine- and threonine-phosphorylated proteins. Also acts as a lipid phosphatase, removing the phosphate in the D3 position of the inositol ring from phosphatidylinositol 3,4,5-trisphosphate, phosphatidylinositol 3,4-diphosphate, phosphatidylinositol 3-phosphate and inositol 1,3,4,5-tetrakisphosphate with order of substrate preference in vitro PtdIns(3,4,5)P3 > PtdIns(3,4)P2 > PtdIns3P > Ins(1,3,4,5)P4. The lipid phosphatase activity is critical for its tumor suppressor function. Antagonizes the PI3K-AKT/PKB signaling pathway by dephosphorylating phosphoinositides and thereby modulating cell cycle progression and cell survival. The unphosphorylated form cooperates with AIP1 to suppress AKT1 activation. Dephosphorylates tyrosine-phosphorylated focal adhesion kinase and inhibits cell migration and integrin-mediated cell spreading and focal adhesion formation. Plays a role as a key modulator of the AKT-mTOR signaling pathway controlling the tempo of the process of newborn neurons integration during adult neurogenesis, including correct neuron positioning, dendritic development and synapse formation. May be a negative regulator of insulin signaling and glucose metabolism in adipose tissue. The nuclear monoubiquitinated form possesses greater apoptotic potential, whereas the cytoplasmic nonubiquitinated form induces less tumor suppressive ability. In motile cells, suppresses the formation of lateral pseudopods and thereby promotes cell polarization and directed movement.
      Isoform alpha: Functional kinase, like isoform 1 it antagonizes the PI3K-AKT/PKB signaling pathway. Plays a role in mitochondrial energetic metabolism by promoting COX activity and ATP production, via collaboration with isoform 1 in increasing protein levels of PINK1.
    • Tissue specificity
      Expressed at a relatively high level in all adult tissues, including heart, brain, placenta, lung, liver, muscle, kidney and pancreas.
    • Involvement in disease
      Cowden syndrome 1
      Lhermitte-Duclos disease
      Bannayan-Riley-Ruvalcaba syndrome
      Squamous cell carcinoma of the head and neck
      Endometrial cancer
      PTEN mutations are found in a subset of patients with Proteus syndrome, a genetically heterogeneous condition. The molecular diagnosis of PTEN mutation positive cases classifies Proteus syndrome patients as part of the PTEN hamartoma syndrome spectrum. As such, patients surviving the early years of Proteus syndrome are likely at a greater risk of developing malignancies.
      Glioma 2
      VACTERL association with hydrocephalus
      Prostate cancer
      Macrocephaly/autism syndrome
      A microdeletion of chromosome 10q23 involving BMPR1A and PTEN is a cause of chromosome 10q23 deletion syndrome, which shows overlapping features of the following three disorders: Bannayan-Zonana syndrome, Cowden disease and juvenile polyposis syndrome.
    • Sequence similarities
      Contains 1 C2 tensin-type domain.
      Contains 1 phosphatase tensin-type domain.
    • Domain
      The C2 domain binds phospholipid membranes in vitro in a Ca(2+)-independent manner; this binding is important for its tumor suppressor function.
    • Post-translational
      modifications
      Constitutively phosphorylated by CK2 under normal conditions. Phosphorylated in vitro by MAST1, MAST2, MAST3 and STK11. Phosphorylation results in an inhibited activity towards PIP3. Phosphorylation can both inhibit or promote PDZ-binding. Phosphorylation at Tyr-336 by FRK/PTK5 protects this protein from ubiquitin-mediated degradation probably by inhibiting its binding to NEDD4. Phosphorylation by ROCK1 is essential for its stability and activity. Phosphorylation by PLK3 promotes its stability and prevents its degradation by the proteasome.
      Monoubiquitinated; monoubiquitination is increased in presence of retinoic acid. Deubiquitinated by USP7; leading to its nuclear exclusion. Monoubiquitination of one of either Lys-13 and Lys-289 amino acid is sufficient to modulate PTEN compartmentalization. Ubiquitinated by XIAP/BIRC4.
    • Cellular localization
      Secreted. May be secreted via a classical signal peptide and reenter into cells with the help of a poly-Arg motif and Cytoplasm. Nucleus. Nucleus, PML body. Monoubiquitinated form is nuclear. Nonubiquitinated form is cytoplasmic. Colocalized with PML and USP7 in PML nuclear bodies. XIAP/BIRC4 promotes its nuclear localization.
    • Information by UniProt
    • Database links
    • Alternative names
      • 10q23del antibody
      • BZS antibody
      • DEC antibody
      • GLM2 antibody
      • MGC11227 antibody
      • MHAM antibody
      • MMAC1 antibody
      • MMAC1 phosphatase and tensin homolog deleted on chromosome 10 antibody
      • Mutated in multiple advanced cancers 1 antibody
      • Phosphatase and tensin homolog antibody
      • Phosphatase and tensin like protein antibody
      • Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN antibody
      • Pten antibody
      • PTEN_HUMAN antibody
      • PTEN1 antibody
      • TEP1 antibody
      see all

    Images



    • Predicted band size : 47 kDa

      Lane 1: Wild-type HAP1 cell lysate (20 µg)
      Lane 2: PTEN knockout HAP1 cell lysate (20 µg)
      Lanes 1 and 2: Merged signal (red and green). Green - ab170941 observed at 47 kDa. Red - loading control, ab8245, observed at 37 kDa.


      ab170941 was shown to specifically react with PTEN in wild-type HAP1 cells. No band was observed when PTEN knockout samples were used. Wild-type and PTEN knockout samples were subjected to SDS-PAGE, ab170941 and ab8245 (loading control to GAPDH) were diluted 1/500 and 1/1000 respectively and incubated overnight at 4°C. Blots were developed with Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed (ab216773) and Goat anti-Mouse IgG H&L (IRDye® 680RD) preadsorbed (ab216776) secondary antibodies at 1/10,000 dilution for 1hr at room temperature before imaging.

    • Immunocytochemistry/Immunofluorescence analysis of HeLa cells labelling PTEN with purified ab170941 at a dilution of 1/500. Cells were fixed with 4% paraformaldehyde and permeabilized with 0.1% Triton X-100. ab150077, an Alexa Fluor® 488-conjugated goat anti-rabbit IgG (1/1000) was used as the secondary antibody. Nuclei counterstained with DAPI (blue).

      Control: PBS only.

    • Immunohistochemical analysis of paraffin-embedded Human breast carcinoma tissue labeling PTEN with ab170941 at 1/50 dilution.

    • Flow Cytometry analysis of HeLa (human cervix adenocarcinoma) cells labeling PTEN with purified ab170941 at 1/120 dilution(10ug/ml) (red). Cells were fixed with 80% methanol and permeabilised with 0.1% Tween-20. A Goat anti rabbit IgG (Alexa Fluor® 488)(ab150077)(1/2000 dilution) was used as the secondary antibody. Rabbit monoclonal IgG (Black)(ab172730) was used as the isotype control, cells without incubation with primary antibody and secondary antibody (Blue) were used as the unlabeled control.

    • All lanes : Anti-PTEN antibody [EPR9941-2] (ab170941) at 1/1000 dilution

      Lane 1 : HeLa cell lysates
      Lane 2 : MCF7 cell lysates
      Lane 3 : 293T cell lysates

      Lysates/proteins at 10 µg per lane.


      Predicted band size : 47 kDa
    • Immunohistochemical analysis of paraffin-embedded Human colon tissue labeling PTEN with ab170941 at 1/50 dilution.

    References

    This product has been referenced in:
    • Liu H  et al. PI3K/AKT/mTOR pathway promotes progestin resistance in endometrial cancer cells by inhibition of autophagy. Onco Targets Ther 10:2865-2871 (2017). WB ; Human . Read more (PubMed: 28652768) »

    See 1 Publication for this product

    Customer reviews and Q&As

    Application
    Immunocytochemistry/ Immunofluorescence
    Sample
    Human Cell (Keratinocyte (HaCaT))
    Permeabilization
    Yes - 0.2% Tritonx100
    Specification
    Keratinocyte (HaCaT)
    Fixative
    Paraformaldehyde
    Username

    Dr. Ann Wheeler

    Verified customer

    Submitted Jul 05 2017

    Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"

    Sign up